Net revenue growth due to first shipments of adult-use recreational product during the period
Consists of gross revenue of $14.4 million less excise taxes and returns of $2.0 million
Adjusted Gross Margin (a non-IFRS measure)1 equal to $8.8 million up from $1.6 million in prior quarter
Cash cost of cultivation (a non-IFRS measure)1 equal to $0.56/dried flower equivalent gram ($0.74 “all-in” including non-cash costs) down from $0.62 ($0.83 “all-in”) in the prior quarter
MONCTON, NB, Jan. 28, 2019 /CNW/ – Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, is pleased to announce its first quarter results for fiscal 2019. The Company’s fiscal first quarter encompasses operations up to and including November 30, 2018 and as a result, includes the impact on revenue of adult-use recreational cannabis for part of the quarter, which was legalized on October 17, 2018.
“The first quarter of 2019 is just the start of what we expect to be a year of tremendous growth,” said Greg Engel, the Company’s Chief Executive Officer. “We’ve always believed the Moncton Campus would be a competitive advantage for us being able to produce high-quality indoor-grown product at low cash cost of cultivation. Our first quarter results confirmed that as we reported an adjusted gross margin of 71%.”
The Company’s net revenue for the quarter was limited by post-harvest (extraction, packaging, excising and labelling) capabilities which it aggressively looks to augment and gain greater efficiencies on.
“While we continue to work hard to take advantage of our enviable inventory build to drive increased sales we are already well underway preparing for the derivative and edibles launch during the fall of 2019,” remarked Greg.
Note: financial figures relating to prior periods have been restated due to the reclassification of discontinued operations and the reclassification of shipping expense from selling and marketing expense to cost of sales.
Select Highlights for the First Quarter of Fiscal 2019
The Company is proud to report record net sales from continuing operations for the three months ended November 30, 2018 (Q1’2019) of $12.4 million, up 419% from $2.4 million in Q1’2018, and up 287% from $3.2 million in Q4’2018.
Gross margin increased to $51.7 million in Q1’2019 from $1.3 million in Q1’2018 and $32.5 million in Q4’2018. Excluding fair value adjustments on biological assets (“adjusted gross margin”) these figures would be $8.8 million, $0.6 million, and $1.6 million, respectively.
Gross margin percentage, excluding fair value adjustments on biological assets, increased to a record 71% during Q1’19 compared to 25% in the prior year comparative quarter and 50% in Q4’2018.
Reported net income from continuing operations was $29.5 million, or $0.195 per share on a diluted basis, for Q1’2019, up from a net loss of $(1.2) million, or $(0.012) per share on a diluted basis, in Q1’2018, and net income of $18.0 million, or $0.152 per share on a diluted basis, in Q4’2018.
Free cash flow, a non-IFRS financial measure1 defined by the Company as net income before income tax, depreciation, share-based compensation, and the fair value adjustment to biological assets and inventory, was positive for the first time at $2.9 million for Q1’2019 versus $(0.7) million for the prior year comparative quarter and $(3.6) million for Q4’2018.
Fiscal 2019 sales will continue to be dominated by adult-use recreational revenue and Q2’19 will represent the first full quarter of adult-use recreational sales for the Company.
The Company is almost two months into Q2 and expects net revenue for the quarter to be at least twice that of Q1 but reminds investors that actual net revenue sales may deviate materially from forecasts.2
The Company reported inventories of $91.4 million up from $45.0 million at year-end August 31, 2018. Organigram continues to build inventories as it continues to ramp up its packaging, labelling, extraction and excise stamping capabilities.
The Company is also actively looking at outsourcing part of its “available for extraction” inventory balance as it represented approximately $38.0 of the $91.4 million inventory balance at quarter-end.
The budget for Phase 4 of the Moncton Campus expansion has increased from the original $110 estimate to $120 to $125 million due to increased cost of steel, timing of winter construction, and expedited timelines. Phase 4A is expected to come online in April 2019 with 31 grow rooms, 4B in August 2019 with 32 grow rooms, and 4C in the Fall of 2019 with 29 grow rooms bringing the Company’s target production capacity to 62,000 kg/yr, 89,000 kg/yr, and 113,000 kg/yr, respectively. The Company had spent approximately $37 million on Phase 4 by the end of Q1’19.3
Operational Highlights (includes events after quarter-end)
Sales and Marketing
Q1’2019 was the strongest sales quarter for Organigram yet. With the launch of the adult-use recreational market coupled with ongoing medical sales, the Company not only experienced its highest sales quarter of all time, it also surpassed in a single quarter what it has historically done in an entire year of sales on the medical side.
The Company is currently focused on becoming an official supplier in the province of Quebec which, if completed, would secure distribution for Organigram in all 10 provinces.
The Company continues to build its sales infrastructure with a high-quality sales team including field sales representatives and sales management to help to work with retailers and educate staff at the retailer level on Organigram’s various brands.
Looking forward, the Company will continue to expand production capacity and to make preparations for the introduction of a range of derivative based products, including edibles and vaporizable products.
Other Milestones and Strategic Initiatives
Investment in Hyasynth – on September 13, 2018 the Company entered into a strategic investment by way of convertible secured debentures of Hyasynth Biologicals Inc., a biotech company based in Montreal and leader in the field of cannabinoid science and biosynthesis. The initial investment of $5 million can increase up to $10 million upon achievement by Hyasynth of certain funding milestones. Please refer to the press release dated September 13, 2018 for further details on this transaction.
Investment in Eviana – on October 2, 2018 the Company completed a $5 million private placement senior unsecured convertible debenture investment in Eviana Health Corporation, a CSE listed company with hemp operations in Serbia. Organigram also entered into an offtake agreement with Eviana, whereby Organigram has the right, but not the obligation, to purchase up to and including 25% of Eviana’s annual CBD production for a period of five years from when it is first made commercially available by Eviana at 95% of the agreed raw CBD oil wholesale market price. Please refer to the press release dated October 2, 2018 for further details on this transaction.
Investment in Alpha-Cannabis Germany – on October 17, 2018 the Company announced a definitive agreement whereby the Company makes a €1.625 million (approximately $2.44 million CAD) investment in Alpha-Cannabis Germany paid in cash with another €875,000 (approximately $1.35 million CAD) payable in the form of Organigram shares on the achievement of certain milestones. Please refer to the press release dated October 17, 2018 for further details on this transaction.
On January 21, 2019, the Company entered into an agreement with 1812 Hemp, a New Brunswick based industrial hemp research company to secure supply and support research and development on the genetic improvement of hemp through traditional plant breeding methods. As part of the deal Organigram has access to approximately 6,000 kg of dried hemp flower harvested in the fall of 2018, which it intends to purchase and begin to send for extraction within the first calendar quarter of 2019.
The following results include sales to the adult-use recreational market, which began in September to meet demand for the launch on October 17, 2018.
Summary of Financial Results
(in CAD $000s except for per share amounts)
Sales recovery (returns)
Cost of sales (incl. indirect production)
Gross margin (excluding FV adjustment)1
FV adjust on bio assets and inventories
General and administrative
Sales and marketing
Share-based compensation (non-cash)
Income (loss) from continuing operations
Net financing costs and investment (income)
Income tax expense
Net income (loss) from continuing operations
Loss from discontinued operations
Net income (loss) and comprehensive income
Net income (loss) from continuing operations per common share, basic
Net income (loss) from continuing operations per common share, diluted
Net income (loss) from discontinued operations per common share, basic
Net income (loss) from discontinued operations per common share, diluted
Selected Balance Sheet Highlights and Financial Position
(in $000 except for per share amounts)
Cash and short-term investments
Other current assets
Property, plant and equipment
Other non-current assets
Total Liabilities and Shareholders’ Equity
(in CAD $000s)
Convertible debentures carrying value
(with face value in parentheses)
Total long-term debt and shareholders’ equity
Restricted share units
Convertible debentures (if converted at $5.42)
During the three months ended November 30, 2018, approximately $14.9 million of face value of debentures were converted into common shares at a conversion price of $5.42, leaving approximately $98.1 million of the face value of debentures outstanding.
Outstanding share count as at January 25, 2019 is as follows:
Restricted share units
Convertible debentures (if converted at $5.42)
About Organigram Holdings Inc.
Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.